Purpose: The pharmacology, pharmaceutics, clinical efficacy, adverse effects, cost, and dosage and administration of long-acting risperidone injection are reviewed. Summary: Risperidone is the first ...

The US Food and Drug Administration has approved the first once-monthly subcutaneous injection of risperidone (Perseris, Indivior) for the treatment of schizophrenia in adults. Perseris uses an ...

What Is Uzedy, and Why Does It Matter? Uzedy is a long-acting injectable form of risperidone, a medicine used to treat serious mental health conditions like schizophrenia and bipolar I disorder (BD-I) ...

The first under-the-skin, long-acting risperidone injection offers a new maintenance option for adults with bipolar 1 disorder. For anyone managing bipolar 1 disorder, staying consistent with daily ...

Uzedy administered once every 2 months is not recommended for the maintenance treatment of bipolar I disorder. The Food and Drug Administration (FDA) has approved Uzedy ® (risperidone extended-release ...

TITUSVILLE, N.J., Oct. 9 /PRNewswire-FirstCall/ -- Patients with schizophrenia now have a new administration option for RISPERDAL(R) CONSTA(R) ([risperidone] Long ...

Please provide your email address to receive an email when new articles are posted on . The FDA approved a long-acting subcutaneous risperidone injection for the treatment of schizophrenia in adults.

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com. Rates of adverse events were similar in both dosing ...

About Risperidone Extended-Release Injectable Suspension for Subcutaneous Use The extended-release subcutaneous risperidone injection is an investigational once-monthly or once-every-two-months ...

TEL AVIV, Israel & PARIS--(BUSINESS WIRE)--Teva Pharmaceuticals Industries Ltd. (NYSE and TASE: TEVA) and MedinCell (Euronext: MEDCL) today announced positive results for study TV46000-CNS-30072 (the ...